Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05565378 · ClinicalTrials.gov registry record · Phase 2

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

A Phase 2 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 2
Development phase
351
Enrollment target
20
Study locations

NCT05565378 is a Phase 2 study of Lung Cancer, Non-Small Cell that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 351 participants, above the 296-participant average among 10 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05565378, a Phase 2 study of Lung Cancer, Non-Small Cell, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
351 participants
Enrollment target
20
Study locations

Study Summary

This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.

Conditions Studied

Lung Cancer, Non-Small Cell

Interventions

  • DRUG Pembrolizumab
  • DRUG Dostarlimab
  • DRUG Belrestotug
  • DRUG Nelistotug

Study Locations (20)

Other

  • GSK Investigational Site - Buenos Aires
  • GSK Investigational Site - Cipoletti Rio Negro
  • GSK Investigational Site - Ciudad Autonoma de Buenos Aire
  • GSK Investigational Site - Ciudad Autonoma de Buenos Aire
  • GSK Investigational Site - Florida
  • GSK Investigational Site - Mar del Plata
  • GSK Investigational Site - San Juan
  • GSK Investigational Site - Santa Fe
  • GSK Investigational Site - Wilrijk
  • GSK Investigational Site - Barretos
  • GSK Investigational Site - Porto Alegre
  • GSK Investigational Site - São Paulo
  • GSK Investigational Site - Vitória
  • GSK Investigational Site - Oulu
  • GSK Investigational Site - Tampere
  • GSK Investigational Site - Turku

Florida

  • GSK Investigational Site - Plantation

New Mexico

  • GSK Investigational Site - Albuquerque

Tennessee

  • GSK Investigational Site - Chattanooga

West Virginia

  • GSK Investigational Site - Morgantown

Trial Details

FieldValue
Enrollment Target 351 participants
Start Date 2022-10-14
Est. Completion 2027-02-26
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05565378

The ClinicalTrials.gov registry entry for NCT05565378 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 296-participant average among 10 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (19% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer, Non-Small Cell appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT05565378 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Florida, New Mexico.

Frequently Asked Questions

What is clinical trial NCT05565378 about?

NCT05565378 is a clinical study titled "A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer". This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Dru...

What is the current status of trial NCT05565378?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 351 participants. The study started on 2022-10-14. Estimated completion is 2027-02-26.

What conditions does trial NCT05565378 study?

This clinical trial studies the following conditions: Lung Cancer, Non-Small Cell.

What interventions are being tested in trial NCT05565378?

The interventions under investigation include: Pembrolizumab (DRUG), Dostarlimab (DRUG), Belrestotug (DRUG), Nelistotug (DRUG).

Who is sponsoring clinical trial NCT05565378?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05565378 being conducted?

This trial has 20 study locations across Florida, New Mexico, Tennessee, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer, Non-Small Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer, Non-Small Cell

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.